share_log

Plus Therapeutics Announces First Patient Dosed In ReSPECT-GBM Phase 2b Trial Of Rhenium (186Re) Obisbemeda For Treatment Of Recurrent Glioblastoma

Benzinga Real-time News ·  Jan 18, 2023 07:02
Plus Therapeutics Announces First Patient Dosed In ReSPECT-GBM Phase 2b Trial Of Rhenium (186Re) Obisbemeda For Treatment Of Recurrent Glioblastoma
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment